Literature DB >> 28923766

Development of stability-enhanced ternary solid dispersions via combinations of HPMCP and Soluplus® processed by hot melt extrusion.

Ahmad B Albadarin1, Catherine B Potter2, Mark T Davis2, Javed Iqbal2, Sachin Korde3, Sudhir Pagire3, Anant Paradkar3, Gavin Walker2.   

Abstract

The aim of this study was to evaluate a novel combination of hydroxypropyl methylcellulose phthalate (HPMCP-HP-50) and Soluplus® polymers for enhanced physicochemical stability and solubility of the produced amorphous solid dispersions (ASDs). This was achieved using hot melt extrusion (HME) to convert the crystalline active pharmaceutical ingredient (API) into a more soluble amorphous form within the ternary systems. Itraconazole (ITZ), a Biopharmaceutics Classification System class II (BCS II) API, was selected as the model drug. The ASDs were characterized by Powder X-Ray diffraction (PXRD), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), Fourier Transform Infrared (FTIR) spectroscopy, Solid State Nuclear Magnetic Resonance (ssNMR) and dissolution studies. The data showed that the ASDs were physically and chemically stable at 20°C and 50% RH over 12 months. PXRD results indicated that the ITZ in the ASDs was in the amorphous state and no recrystallization occurred. DSC scans confirmed that each formulation exhibited a single intermediate glass transition (Tg), around 96.4°C, indicating that ITZ was completely miscible in the polymeric blends of HPMCP and Soluplus® at up to 30% (w/w) drug loading and that the two polymers were miscible with each other in the presence of ITZ. The FTIR analysis indicated the formation of strong hydrogen bonding between ITZ, HPMCP and Soluplus®. The dissolution end-point of the ASDs was determined to be approximately 10 times greater than that of the crystalline ITZ.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analytical techniques; Dissolution studies; Enhanced solubility; Itraconazole; Physical stability

Mesh:

Substances:

Year:  2017        PMID: 28923766     DOI: 10.1016/j.ijpharm.2017.09.035

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Preparation and Characterization of pH-Independent Sustained-Release Tablets Containing Hot Melt Extruded Solid Dispersions of Clarithromycin : Tablets Containing Solid Dispersions of Clarithromycin.

Authors:  Qazi Amir Ijaz; Sumera Latif; Qurat-Ul-Ain Shoaib; Memoona Rashid; Muhammad Sohail Arshad; Amjad Hussain; Nadeem Irfan Bukhari; Sohail Riaz; Nasir Abbas
Journal:  AAPS PharmSciTech       Date:  2021-11-12       Impact factor: 3.246

2.  Compatibility and stability studies involving polymers used in fused deposition modeling 3D printing of medicines.

Authors:  Ihatanderson A Silva; Ana Luiza Lima; Tais Gratieri; Guilherme M Gelfuso; Livia L Sa-Barreto; Marcilio Cunha-Filho
Journal:  J Pharm Anal       Date:  2021-09-20

Review 3.  Quality-by-design in hot melt extrusion based amorphous solid dispersions: An industrial perspective on product development.

Authors:  Arun Butreddy; Suresh Bandari; Michael A Repka
Journal:  Eur J Pharm Sci       Date:  2020-11-28       Impact factor: 4.384

4.  A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier.

Authors:  Hiroyuki Takabe; Zachary N Warnken; Yajie Zhang; Daniel A Davis; Hugh D C Smyth; John G Kuhn; Steve Weitman; Robert O Williams Iii
Journal:  Pharmaceutics       Date:  2018-05-19       Impact factor: 6.321

5.  Processing of Polyvinyl Acetate Phthalate in Hot-Melt Extrusion-Preparation of Amorphous Solid Dispersions.

Authors:  Marius Monschke; Kevin Kayser; Karl G Wagner
Journal:  Pharmaceutics       Date:  2020-04-09       Impact factor: 6.321

6.  Improved Bioavailability of Poorly Water-Soluble Drug by Targeting Increased Absorption through Solubility Enhancement and Precipitation Inhibition.

Authors:  Ju-Hyun Lee; Chulhun Park; Kwon-Yeon Weon; Chin-Yang Kang; Beom-Jin Lee; Jun-Bom Park
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.